# Reverse Sural Flap Venous Congestion Successfully Managed With Enoxaparin in a Male Patient With a Traumatic Foot Crush Injury: A Case Report

**Authors:** Jonathan Velasco-Bustamante, Dagmar Velasco-Bustamante, Cecibel Bravo-Romero, Cesar Nacimba-Aman, Wilson S Peñafiel-Pallares

PMC · DOI: 10.7759/cureus.101926 · Cureus · 2026-01-20

## TL;DR

A patient with a foot injury developed venous congestion after a reverse sural flap surgery, but enoxaparin treatment helped save most of the flap.

## Contribution

This case report demonstrates the successful use of enoxaparin to manage venous congestion in a reverse sural flap.

## Key findings

- Venous congestion after a reverse sural flap was successfully treated with a local enoxaparin protocol.
- Approximately 80% of the flap remained viable following the intervention.
- The case highlights the potential clinical utility of low-molecular-weight heparin in flap salvage.

## Abstract

The reverse sural flap is a commonly used surgical option for soft-tissue defects of the distal leg, ankle, and heel in hospitals where microsurgical capabilities are limited. However, one of its most frequent complications is venous congestion, which can lead to partial or total flap necrosis if not promptly addressed. We present the case of a patient with a traumatic crush injury of the right ankle, reconstructed with a reverse-flow sural flap that subsequently developed venous congestion in the immediate postoperative period (<12 hours). A local subcutaneous enoxaparin protocol (low-molecular-weight heparin) was implemented as a salvage strategy. This intervention successfully reversed the clinical signs of venous congestion and preserved approximately 80% of the flap's viability. This report discusses the underlying pathophysiology, the applied protocol, previous evidence, and the clinical implications of this approach.

## Full-text entities

- **Diseases:** venous thrombosis (MESH:D020246), coagulation disorders (MESH:D001778), infection (MESH:D007239), congestion (MESH:D002311), Foot Crush Injury (MESH:D000071576), dorsal foot defect (MESH:D000092142), spasm (MESH:D013035), thrombosis (MESH:D013927), Soft-tissue defect (MESH:D017695), necrosis (MESH:D009336), Flap (MESH:D000070600), edema (MESH:D004487), diabetes mellitus (MESH:D003920), torsion (MESH:D050723), venous outflow impairment (MESH:D006502), inflammatory (MESH:D007249), hematoma (MESH:D006406), defects (MESH:D000013), peripheral vascular disease (MESH:D016491), venous stasis (MESH:D054070), hypoxemia (MESH:D000860), ischemia (MESH:D007511), Venous Congestion (MESH:D006940), bleeding (MESH:D006470)
- **Chemicals:** LMWH (MESH:D006495), heparin (MESH:D006493), alcohol (MESH:D000438), carbon dioxide (MESH:D002245), oxygen (MESH:D010100), Enoxaparin (MESH:D017984)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12919947/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12919947/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12919947/full.md

---
Source: https://tomesphere.com/paper/PMC12919947